Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Paclitaxel-Coated Balloons Versus Sirolimus-Coated Balloons for Coronary Artery Lesions : A Nationwide Cohort Study From SCAAR

von Koch, Sacharias LU orcid ; Yndigegn, Troels LU ; Koul, Sasha LU ; Zwackman, Sammy ; Desta, Liyew ; Angerås, Oskar ; Omerovic, Elmir ; Böhm, Felix ; Fröbert, Ole and Grimfjärd, Per , et al. (2026) In Journal of the Society for Cardiovascular Angiography and Interventions 5(6).
Abstract

Background Sirolimus-coated balloons (SCB) are a potential alternative to paclitaxel-coated balloons (PCB) in the context of percutaneous coronary intervention (PCI). However, comparative data between SCB and PCB remain limited. We aimed to compare the outcome of PCI with contemporary PCB or SCB in a real-world clinical setting. Methods The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to include all patients undergoing PCI with PCB or SCB between January 1, 2022 and May 16, 2025. The primary outcome was target segment revascularization assessed on coronary artery segment level. Outcome was assessed using multivariable-adjusted Cox regression. Results A total of 7855 PCB-treated and 502 SCB-treated segments were... (More)

Background Sirolimus-coated balloons (SCB) are a potential alternative to paclitaxel-coated balloons (PCB) in the context of percutaneous coronary intervention (PCI). However, comparative data between SCB and PCB remain limited. We aimed to compare the outcome of PCI with contemporary PCB or SCB in a real-world clinical setting. Methods The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to include all patients undergoing PCI with PCB or SCB between January 1, 2022 and May 16, 2025. The primary outcome was target segment revascularization assessed on coronary artery segment level. Outcome was assessed using multivariable-adjusted Cox regression. Results A total of 7855 PCB-treated and 502 SCB-treated segments were included. PCB was less frequently used for in-stent restenosis (28.0% vs 34.3%). After a 1-year follow-up period, no difference was observed between PCB and SCB in terms of target segment revascularization (3.3% vs 5.8%; hazard ratio [HR], 1.37; 95% CI, 0.83-2.25), target vessel revascularization (5.2% vs 8.1%; HR, 1.24; 95% CI, 0.78-1.97), restenosis (2.8% vs 4.4%; HR, 1.44; 95% CI, 0.85-2.44), myocardial infarction (3.1% vs 4.9%; HR, 0.74; 95% CI, 0.41-1.32), repeat PCI (8.8% vs 10.8%; HR, 1.04; 95% CI, 0.72-1.51), or all-cause mortality (4.4% vs 3.2%; HR, 1.37; 95% CI, 0.34-1.15). Conclusions In this study investigating outcome after PCI with drug-coated balloons, no statistically significant differences in 1-year clinical outcomes were observed between PCB and SCB.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
drug-coated balloons, paclitaxel-coated balloons, percutaneous coronary intervention, sirolimus-coated balloons, Swedish Coronary Angiography and Angioplasty Registry
in
Journal of the Society for Cardiovascular Angiography and Interventions
volume
5
issue
6
article number
105315
publisher
Elsevier
external identifiers
  • scopus:105041225255
ISSN
2772-9303
DOI
10.1016/j.jscai.2026.105315
language
English
LU publication?
yes
id
1e313eca-17c0-4ce9-976c-acc5933ad44e
date added to LUP
2026-07-02 12:41:22
date last changed
2026-07-02 12:42:35
@article{1e313eca-17c0-4ce9-976c-acc5933ad44e,
  abstract     = {{<p>Background Sirolimus-coated balloons (SCB) are a potential alternative to paclitaxel-coated balloons (PCB) in the context of percutaneous coronary intervention (PCI). However, comparative data between SCB and PCB remain limited. We aimed to compare the outcome of PCI with contemporary PCB or SCB in a real-world clinical setting. Methods The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to include all patients undergoing PCI with PCB or SCB between January 1, 2022 and May 16, 2025. The primary outcome was target segment revascularization assessed on coronary artery segment level. Outcome was assessed using multivariable-adjusted Cox regression. Results A total of 7855 PCB-treated and 502 SCB-treated segments were included. PCB was less frequently used for in-stent restenosis (28.0% vs 34.3%). After a 1-year follow-up period, no difference was observed between PCB and SCB in terms of target segment revascularization (3.3% vs 5.8%; hazard ratio [HR], 1.37; 95% CI, 0.83-2.25), target vessel revascularization (5.2% vs 8.1%; HR, 1.24; 95% CI, 0.78-1.97), restenosis (2.8% vs 4.4%; HR, 1.44; 95% CI, 0.85-2.44), myocardial infarction (3.1% vs 4.9%; HR, 0.74; 95% CI, 0.41-1.32), repeat PCI (8.8% vs 10.8%; HR, 1.04; 95% CI, 0.72-1.51), or all-cause mortality (4.4% vs 3.2%; HR, 1.37; 95% CI, 0.34-1.15). Conclusions In this study investigating outcome after PCI with drug-coated balloons, no statistically significant differences in 1-year clinical outcomes were observed between PCB and SCB.</p>}},
  author       = {{von Koch, Sacharias and Yndigegn, Troels and Koul, Sasha and Zwackman, Sammy and Desta, Liyew and Angerås, Oskar and Omerovic, Elmir and Böhm, Felix and Fröbert, Ole and Grimfjärd, Per and James, Stefan and Erlinge, David and Mohammad, Moman A.}},
  issn         = {{2772-9303}},
  keywords     = {{drug-coated balloons; paclitaxel-coated balloons; percutaneous coronary intervention; sirolimus-coated balloons; Swedish Coronary Angiography and Angioplasty Registry}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Elsevier}},
  series       = {{Journal of the Society for Cardiovascular Angiography and Interventions}},
  title        = {{Paclitaxel-Coated Balloons Versus Sirolimus-Coated Balloons for Coronary Artery Lesions : A Nationwide Cohort Study From SCAAR}},
  url          = {{http://dx.doi.org/10.1016/j.jscai.2026.105315}},
  doi          = {{10.1016/j.jscai.2026.105315}},
  volume       = {{5}},
  year         = {{2026}},
}